Bayesian Analysis

A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities

Suyu Liu and Jing Ning

Full-text: Open access

Abstract

We propose a Bayesian adaptive dose-finding design for drug combination trials with delayed toxicity. We model the dose-toxicity relationship using the Finney model, a model widely used in drug-drug interaction studies. The intuitive interpretations of the Finney model facilitate incorporating the available prior dose-toxicity information from single-agent trials into combination trials through prior elicitation. We treat unobserved delayed toxicity outcomes as missing data and handle them using Bayesian data augmentation. We conduct extensive simulation studies to examine the operating characteristics of the proposed method under various practical scenarios. Results show that the proposed design is safe and able to select the target dose combinations with high probabilities.

Article information

Source
Bayesian Anal., Volume 8, Number 3 (2013), 703-722.

Dates
First available in Project Euclid: 9 September 2013

Permanent link to this document
https://projecteuclid.org/euclid.ba/1378729925

Digital Object Identifier
doi:10.1214/13-BA839

Mathematical Reviews number (MathSciNet)
MR3102231

Zentralblatt MATH identifier
1329.62431

Keywords
Adaptive design Late-onset toxicity Combining drugs Missing data Maximum tolerated dose Phase I trial

Citation

Liu, Suyu; Ning, Jing. A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Bayesian Anal. 8 (2013), no. 3, 703--722. doi:10.1214/13-BA839. https://projecteuclid.org/euclid.ba/1378729925


Export citation

References

  • Braun, T. M. and Wang, S. (2010). “A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.” Biometrics, 66: 805–812.
  • Cheung, K. Y. and Chappell, R. (2000). “Sequential designs for phase I clinical trials with late-onset toxicities.” Biometrics, 56: 1177–1182.
  • Coia, L. R., Myerson, R., and Tepper, J. E. (1995). “Late effects of radiation therapy on the gastrointestinal tract.” International Journal of Radiation Oncology, Biology, Physics, 31: 1213–1236.
  • Conaway, M. R., Dunbar, S., and Peddada, S. D. (2004). “Designs for single- or multiple-agent phase I trials.” Biometrics, 60: 661–669.
  • Cooper, J. S., Fu, K., Marks, J., and Silverman, S. (1995). “Late effects of radiation therapy in the head and neck region.” International Journal of Radiation Oncology, Biology, Physics, 31: 1141–1164.
  • Finney, D. (1971). Probit Analysis. Cambridge: Cambridge University Press.
  • Govindarajulu, Z. (2001). Statistical Techniques in Bioassay. Basel: Karger., 2 edition.
  • Greco, W. R., Bravo, G., and Parsons, J. C. (1995). “The search for synergy: a critical review from a response surface perspective.” Pharmacological Reviews, 47: 331–385.
  • Houede, N., Thall, P. F., Nguyen, H., Paoletti, X., and Kramar, A. (2010). “Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.” Biometrics, 66: 532–540.
  • Loewe, S. and Muischnek, H. (1926). “Effect of combinations: mathematical basis of the problem.” Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 114: 313–326.
  • Mauguen, A., Le Deley, M. C., and Zohar, S. (2011). “Dose-finding approach for dose escalation with overdose control considering incomplete observations.” Statistics in Medicine, 30: 1584–1594.
  • Muler, J. H., McGinn, C. J., Normolle, D., Lawrence, T., Brown, D., Hejna, G., and Zalupski, M. M. (2004). “Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer.” Journal of Clinical Oncology, 22: 238–243.
  • Paoletti, X. and Kramar, A. (2009). “A comparison of model choices for the continual reassessment method in phase I cancer trials.” Statistics in Medicine, 28: 3012–3028.
  • Postel-Vinay, S., Gomez-Roca, C., Molife, L. R., Anghan, B., Levy, A., Judson, I., Bono, J. D., Soria, J., Kaye, S., and Paoletti, X. (2011). “Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?” Journal of Clinical Oncology, 29: 1728–1735.
  • Tanner, M. A. and Wong, W. H. (1987). “The calculation of posterior distributions by data augmentation (with discussion).” Journal of the American Statistical Association, 82: 528–550.
  • Thall, P. F., Millikan, R. E., Müller, P., and Lee, S.-J. (2003). “Dose-finding with two agents in phase I oncology trials.” Biometrics, 59: 487–496.
  • Wages, N. A., Conaway, M. R., and O’Quigley, J. (2011). “Continual Reassessment Method for Partial Ordering.” Biometrics, 67: 1555–1563.
  • Wang, K. and Ivanova, A. (2005). “Two-Dimensional Dose Finding in Discrete Dose Space.” Biometrics, 61: 217–222.
  • Yin, G. and Yuan, Y. (2009a). “Bayesian dose finding in oncology for drug combinations by copula regression.” Journal of the Royal Statistical Society: Series C (Applied Statistics), 58: 211–224.
  • — (2009b). “A latent contingency table approach to dose finding for combinations of two agents.” Biometrics, 27: 866–875.
  • Yuan, Y. and Yin, G. (2008). “Sequential continual reassessment method for two-dimensional dose finding.” Statistics in Medicine, 27: 5664–5678.
  • — (2011). “Robust EM Continual Reassessment Method in Oncology Dose Finding.” Journal of the American Statistical Association, 106: 818–831.